The current P/E ratio of CHRS cannot be calculated, as the latest EPS of -$1.13 is negative. Coherus BioSciences's last PE ratio on record was 5.52 in December 2024.
The mean historical PE ratio of Coherus BioSciences over the last six years is 8.62. Analyzing the last six years, CHRS's PE ratio reached its highest point in the Dec 2019 quarter at 13.96, with a price of $18.01 and an EPS of $1.29. The Dec 2024 quarter saw the lowest point at 5.52, with a price of $1.38 and an EPS of $0.25.
Maximum annual decrease: -32.74% in 2020
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 5.52 | N/A | $1.38 | $0.25 |
2023 | N/A | N/A | $3.33 | -$2.53 |
2022 | N/A | N/A | $7.92 | -$3.76 |
2021 | N/A | N/A | $15.96 | -$3.81 |
2020 | 9.39 | -32.74% | $17.38 | $1.85 |
2019 | 13.96 | N/A | $18.01 | $1.29 |
2018 | N/A | N/A | $9.05 | -$3.22 |
2017 | N/A | N/A | $8.8 | -$4.48 |
2016 | N/A | N/A | $28.15 | -$3.04 |
2015 | N/A | N/A | $22.96 | -$6.01 |
2014 | N/A | N/A | $16.32 | -$10.64 |
2013 | N/A | N/A | N/A | -$16.1 |
2012 | N/A | N/A | N/A | -$15.85 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | N/A | N/A | $0.81 | -$1.13 |
Dec 2024 | 5.52 | N/A | $1.38 | $0.25 |
Sep 2024 | N/A | N/A | $1.04 | -$0.03 |
Jun 2024 | N/A | N/A | $1.73 | -$0.35 |
Mar 2024 | N/A | N/A | $2.39 | -$0.73 |
Dec 2023 | N/A | N/A | $3.33 | -$2.53 |
Sep 2023 | N/A | N/A | $3.74 | -$2.62 |
Jun 2023 | N/A | N/A | $4.27 | -$3.32 |
Mar 2023 | N/A | N/A | $6.84 | -$3.48 |
Dec 2022 | N/A | N/A | $7.92 | -$3.76 |
Sep 2022 | N/A | N/A | $9.61 | -$3.59 |
Jun 2022 | N/A | N/A | $7.24 | -$2.97 |
Mar 2022 | N/A | N/A | $12.91 | -$2.72 |
Dec 2021 | N/A | N/A | $15.96 | -$3.81 |
Sep 2021 | N/A | N/A | $16.07 | -$3.13 |
Stock name | PE ratio | Market cap |
---|---|---|
AMGN Amgen Inc | 25.97 | $154.33B |
RGEN Repligen Corp | N/A | $7.11B |
AGEN Agenus Inc | N/A | $154.36M |
SRPT Sarepta Therapeutics Inc | N/A | $3.89B |
CHRS Coherus BioSciences Inc | N/A | $92.4M |
The current price to earnings ratio of CHRS cannot be determined, as its EPS of -$1.13 is negative.
The highest quarterly PE ratio in the last six years has been 13.96 and it was in the Dec 2019 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.